[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
October 22, 2007

Good Evidence Evaluation for Good Risk Assessment

Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Intern Med. 2007;167(19):2146-2147. doi:10.1001/archinte.167.19.2146-b

We read with great interest the article by Singh et al1 about the proliferation of percutaneous coronary intervention (PCI) after acute myocardial infarction in Ontario, Canada, between 1992 and 2004. The authors used an original methodological approach to demonstrate that the growing use of PCI is mainly attributable to factors other than the emergence of published scientific evidence.1 These findings are of particular importance considering the risk of an underestimated but serious complication: cholesterol crystal embolism (CCE). Indeed, nowadays, the principal risk factor for CCE is the use of invasive vascular procedures.2